Treatment for Peripheral Arterial Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
TSET Health Promotion Research Center, Oklahoma City, OK
Peripheral Arterial Disease+2 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Tobacco cessation treatment is needed for individuals with peripheral artery disease (PAD) to improve symptoms, lower cardiovascular risk, and prevent amputation. While such treatment is effective, many PAD patients do not receive cessation therapy. Participants will receive nicotine replacement therapy, counseling, and and complete questionnaires. We hypothesize that integrating tobacco cessation services into a dedicated PAD clinic (OU CVI Limb Preservation Clinic) can improve tobacco cessation rates and improve PAD-related health outcomes in this at risk population.

Eligible Conditions

  • Peripheral Arterial Disease
  • Peripheral Arterial Disease (PAD)
  • Cessation, Tobacco

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Peripheral Arterial Disease

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Duration of the study (approximately 6 months)

13 weeks post enrollment
Biochemically confirmed abstinence
Week 13
Improvements in PAD
Month 6
Rate of enrollment

Trial Safety

Safety Progress

1 of 3

Other trials for Peripheral Arterial Disease

Trial Design

0 Treatment Group

40 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: duration of the study (approximately 6 months)
Closest Location: TSET Health Promotion Research Center · Oklahoma City, OK
Photo of oklahoma city 1Photo of oklahoma city 2Photo of oklahoma city 3
2022First Recorded Clinical Trial
1 TrialsResearching Peripheral Arterial Disease
3 CompletedClinical Trials

Who is running the clinical trial?

University of OklahomaLead Sponsor
410 Previous Clinical Trials
95,566 Total Patients Enrolled
5 Trials studying Peripheral Arterial Disease
1,115 Patients Enrolled for Peripheral Arterial Disease
Darla E Kendzor, PhDPrincipal InvestigatorUniversity of Oklahoma

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have peripheral artery disease.
You are at least 18 years old.
You are a tobacco user.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.